Takeda and enGene Establish Strategic Alliance to Develop Novel Therapeutics for Gastrointestinal Diseases
Takeda Pharmaceutical Company Ltd. (TOKYO:4502) and enGene, Inc. today announced a strategic alliance to discover, develop and commercialize novel therapies for specialty gastrointestinal (GI) diseases using enGene’s “Gene Pill” gene delivery platform. The strategic alliance will leverage enGene’s expertise and intellectual property position in delivering therapeutic genes to cells of the gut lining by using its proprietary non-viral vector platform.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160111006619/en/
Under the terms of the agreement, enGene will develop up to two undisclosed targets selected by Takeda through pre-clinical proof of concept and IND enabling studies. At that point, Takeda will have an option to exclusively license the global rights for the product candidates.
Following option exercise, Takeda will be responsible for all clinical development and commercialization of those products. enGene will receive an upfront payment and reimbursement of all R&D costs incurred during the development of the selected targets. In addition, enGene is eligible to earn milestone payments for the product candidates based on accomplishment of specific research, clinical, regulatory and commercial milestones. enGene also will receive tiered royalties on future net sales of the collaboration products. Further details of the agreement were not disclosed.
Takeda will also collaborate with enGene in developing Gene Pill into a platform for oral delivery of antibodies. Takeda has the exclusive option to obtain a right of first negotiation for up to three antibody targets.
“We aim to have a positive impact on patients’ lives by translating unique innovations in science into life-changing medicines to treat GI disorders,” said Gareth Hicks, who leads gastroenterology discovery research at Takeda. “Therefore, we are pleased to partner with enGene to further investigate the potential of their ‘Gene Pill’ delivery platform.”
“We are very excited to be collaborating with the team at Takeda to investigate new medicines for the specialty GI market using enGene’s innovative gene delivery platform for the gut,” said Dr. Anthony T. Cheung, chief executive officer and a co-founder of enGene. “In addition to gaining non-dilutive funding to support the development of our own products, this alliance provides our company an excellent opportunity to grow our drug development capabilities through working with a leading pharmaceutical company in the gastroenterology space.”
About enGene, Inc.
enGene Inc. is a privately held biotechnology company developing a versatile, proprietary non-viral vector platform for gene delivery to mucosal cells lining the gut. The vector system can be administered to the intestine via the oral or enema route. enGene is developing its unique gene delivery formulation into an orally available “Gene Pill”, which has the potential to be a platform for oral delivery of a wide range protein drugs. Its primary focus is targeting its technology to enable localize delivery of immune-modulating proteins to the gut for treating various immune disorders.
Located in Osaka, Japan, Takeda (TOKYO:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.
Additional information about Takeda is available through its corporate website, www.takeda.com.
Takeda’s Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future revenues and profitability from or growth or any assumptions underlying any of the foregoing. Statements made in the future tense, and words such as “anticipate,” “expect,” “project,” “continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,” “potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,” “assume,” “will,” “may,” “should,” and similar expressions are intended to qualify as forward-looking statements. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not be obtained in a timely manner, if at all; the conditions to closing of the transaction may not be satisfied; competitive pressures and developments; applicable laws and regulations; the success or failure of product development programs; actions of regulatory authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed products or product candidates in development.
The forward-looking statements contained in this press release speak only as of the date of this press release, and neither enGene nor Takeda undertake any obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made.
Tsuyoshi Tada – Japan
Corporate Communications Dept.
Julia Ellwanger – USA
Dr. Anthony Cheung, Chief Executive Officer
+1-514-332-4888, ext. 204
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
FLIR Launches Thermal Traffic Sensor for Vehicle-to-Everything Communication20.3.2018 07:00 | Pressemelding
FLIR Systems, Inc. (NASDAQ: FLIR) today announced the launch of the FLIR ThermiCam™ V2X, a thermal traffic sensor for the emerging vehicle-to-everything (V2X) technology market. The FLIR V2X-enabled traffic sensor for urban traffic will allow vehicles and traffic infrastructure to communicate and share data in a system that aims to improve motorist, pedestrian, and bicyclist safety and efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320005416/en/ FLIR ThermiCam V2X thermal traffic sensor designed for the emerging vehicle-to-everything (V2X) technology market will communicate with V2X-equipped vehicles. (Photo: Business Wire) V2X technology is an emerging crash avoidance system that relies on the communication of information between nearby vehicles and traffic infrastructure to warn drivers about potentially dangerous situations. In a V2X system, both the vehicles and infrastructure have communication units inst
Shopping on Instagram Goes Global with Shopify20.3.2018 06:00 | Pressemelding
Shopify Inc. (NYSE: SHOP) (TSX: SHOP), the leading multi-channel commerce platform, today announces its expanded integration with Instagram. The “shopping on Instagram” feature that allows businesses to tag products in Instagram posts is now enabled for merchants in eight additional markets: UK, Australia, Canada, Germany, France, Italy, Spain and Brazil. This strategic expansion unlocks potential for Shopify’s merchants to sell to Instagram users all over the world. Instagram, a fun, popular photo-sharing app for mobile devices, is a great venue for Shopify’s hundreds of thousands of merchants in categories such as fashion, jewelry, beauty, furniture and home decor to grow their customer base in a meaningful way. Riding on the successes from the earlier rollout for Shopify’s U.S. merchants, the expanded integration will allow shoppers all over the world to experience this unique commerce feature on Instagram. With the objective of helping our merchants reach more shoppers around the w
Oxford Nanopore Announces £100 Million ($140M) Fundraising from Global Investors20.3.2018 06:00 | Pressemelding
Oxford Nanopore Technologies Ltd, the company behind the only portable real-time DNA/RNA sequencer, MinION, has raised £100M ($140M) in new investment. Funds were raised from global investors including GIC (Singapore), China Construction Bank International (CCBI, China), Hostplus (Australia), and existing investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180319006158/en/ Oxford Nanopore’s novel DNA/RNA sequencing technology: the portable MinION is now being joined by other formats including high-throughput, on-demand PromethION and single-test Flongle (Graphic: Business Wire) The funds will be used to support the Company’s next phase of commercial expansion. This includes a new high-volume, high-tech manufacturing facility in Oxford to meet accelerating demand for Oxford Nanopore’s sequencing technology, and growth of the commercial team that already serves more than 70 countries. The funds raised will also support R
Milrem Robotics is Developing a Firefighting and Search and Rescue UGV20.3.2018 06:00 | Pressemelding
Known mostly for their smart warfare systems – Milrem Robotics – is entering the commercial market with its firefighting and search and rescue unmanned ground vehicle being developed together with rescue services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180319005756/en/ Known mostly for their smart warfare systems - Milrem Robotics - is entering the commercial market with its firefighting and search and rescue unmanned ground vehicle being developed together with rescue services. (Photo: Business Wire) The UGV known as Multiscope Rescue can be equipped with firefighting equipment such as a water tank and a remotely controlled water cannon. It can reach areas that are unreachable by human personnel or too dangerous for firefighters to go into like tunnels or other structures that may collapse at any time. The search and rescue unit can also be equipped with thermal cameras and powerful lights to find missing people in
RagingWire Opens New VA3 Data Center and Ashburn Data Center Campus in the Heart of Famed "Data Center Alley"20.3.2018 02:09 | Pressemelding
RagingWire Data Centers, Inc., the premier data center provider in North America and its parent company NTT Communications (NTT Com), the information and communications technology (ICT) solutions and international communications business within the NTT Group (TOKYO: 9432), today announced the opening of its new Ashburn VA3 Data Center, a state-of-the-art facility with 245,000 square feet of space and 16 megawatts of critical power, located on RagingWire’s new Ashburn Data Center Campus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180319006380/en/ RagingWire new Ashburn VA3 Data Center (Graphic: Business Wire) “With 16 megawatts available today at the new VA3 Data Center and massive scalability in our new Ashburn Data Center Campus, RagingWire has become the destination of choice for hyperscale, high-growth customers in the top data center market in the world,” said RagingWire President and CEO Doug Adams. “Plus our global
FAA Approves AerTrakTM to Comply with Automatic Dependent Surveillance-Broadcast (ADS-B) Operations Mandate19.3.2018 18:19 | Pressemelding
The Federal Aviation Administration (FAA) has issued a Supplemental Type Certificate (STC) for installation of AerSale®’s AerTrak™ system on Boeing 737 NG series aircraft (ST04009NY), to comply with the Automatic Dependent Surveillance-Broadcast (ADS-B) Operations rule, a critical part of the agency’s Next Generation Air Transportation System (NextGen). Beginning January 1, 2020, the FAA has mandated that aircraft operating in airspace defined by 14 CFR § 91.225 must be equipped with an ADS-B Out system that meets the minimum performance requirements of 14 CFR § 91.227. ADS-B provides enhanced navigational accuracy using precise tracking via global positioning satellite (GPS) signals. Reducing risk and improving safety, the technology increases navigational coverage, especially in remote areas beyond radar range. Additionally, ADS-B enables more direct flight plans, thereby saving time, costs, and reducing emissions. “AerTrak is a cost-effective ADS-B Out solution for operators of Boei